Myriad Genetics’ Post

Insightful exploration of circulating tumor DNA (ctDNA) kinetics as a biomarker in adaptive clinical trials. The changes in ctDNA level over time correlate strongly with tumor size variations, potentially offering more precision than traditional radiographic methods after establishing a baseline. #ctDNA #cfDNA #liquidbiopsy #cancerresearch #oncologyresearch #clinicaltrials #biomarkers #cancer #oncology

Should the evidence read positively, MRD is poised to become a dominant surveillance tool for oncology Adaptive Design trials. NGS-based assays align well with a major secular shift we’re seeing with precision oncology drugs—they’re increasingly targeting specific genetic mutations. Solid tumors are an amalgam of many genetically-defined sub-diseases masquerading as a single disease. Unlike imaging, modern MRD assays give researchers a dynamic view into this heterogeneity. #MRDtesting #liquidbiopsy #ngs #biomarkers #MRD

#ASCO2024 is a wrap but in case you missed it. #Labcorp®TissueComplete, a comprehensive genomic profiling service, is now available in Geneva and Shanghai to support global clinical trials. Also, company expands leadership in #liquidbiopsy #comprehensivegenomicprofiling for solid tumors with the integration of #OmniSeq®INSIGHT circulating tumor DNA. Please DM me to learn more. To learn about Labcorp's oncology solutions, visit  https://lnkd.in/e-WgbUxu #Oncology #ClinicalTrials #DrugDevelopment

This powerful partnership aims to transform oncology research. By combining extensive clinical and genomic databases with advanced machine learning, they'll accelerate drug development and precision medicine. This is a big step towards targeted therapies and better outcomes for cancer patients. #CancerResearch #AI #PrecisionMedicine

https://lnkd.in/gbdeS3RE As important a paper, in Journal of Clinical Oncology, in recent years in the field of #ocularoncology and #ocularmelanoma was just brought forth by the Collaborative Ocular Oncology Group, lead by J William Harbour, MD at UT Southwestern. A multi-country effort that has now validated gene expression profiling as well as PRAME, as a risk modifier, in a very clinically relevant patient population. With over 1500 patients followed for over 42 months, a new 4 group stratification predicts melanoma-specific survival at 98.8% for the lowest risk compared to 61% for the highest risk groups. This information will inform clinicians, patients, and - most importantly- clinical trial entry into the future. National Cancer Institute (NCI), Castle Biosciences, Inc.Byers Eye Institute at Stanford, American Society of Clinical Oncology (ASCO), Journal of Clinical Oncology, Zelia Correa, Amy Schefler, Miguel Materin, Thomas Aaberg Jr, Alison Skillet, Ezekiel Weis, Ivana Kim, Scott Walter, Brian Marr, Basil Williams, Scott Oliver, James Dollar, Song Zhang, Tony Tsai, David Reichstein, @eugene Shildkrot, @devron char, Demirci Hakan, @Cameron javid, @dan gomobos, JayPeter Hovland, Christina D.,

In an impressive stride for precision medicine, Alterome Therapeutics, Inc has just unveiled compelling pre-clinical data for their lead AKT1 E17K inhibitor program. Dubbed ALTA-2618, this compound targets a specific mutation found across various aggressive cancers which gives some hope for those patients facing limited treatment avenues 💊🙌 During rigorous preclinical studies, this potential game-changer didn't just inhibit; it showcased remarkable tumor shrinkage, paired with oral bioavailability that's ideal for patient use. Later this year, Alterome will be gearing up for a pivotal phase: first-in-human clinical trials so let's watch this space as ALTA-2618 ventures from bench to bedside, potentially transforming many lives!✅📈 #PrecisionMedicine #CancerResearch #Oncology #AlteromeTherapeutics #ClinicalTrials #ClinicalResearch #MedicalInnovation #LifeScience #ElixirAssociates #StaffingPartner

More than 40% of all cancers and 50% of the oncology clinical development pipeline are hematological malignancies. Yet the research and technology solutions supporting translational research, clinical trial design, and post-approval evidence generation have lagged what is available for solid tumor cancers. Over the course of the last few years, ConcertAI has been working to redefine the real-world data, insight technologies, and clinical trial solutions for these diseases. We are now pleased to announce our partnership with NeoGenomics Laboratories, the leader in hematology and hematological malignancy testing, covering up to 40% of patients. With this novel relationship we can provide the population coverage, biomarker depth, and longitudinal coverage required for pre-approval and post-approval research. We are further aligning our solutions for clinical trial design and planning. More to come. #concertai #hematology #ash23 #ash2023 https://lnkd.in/eDxFZuZx

Tumor patients with mutant RAS possess a worse prognosis and shorter overall survival compared with those patients without RAS mutation. Emerging strategies have been recently developed for RAS-targeting therapy. This blog post explores the ‘undruggable’ oncology target RAS, inhibitory techniques used on downstream pathways, and the preclinical models available to test up-and-coming RAS targeted agents. #CancerResearch #Oncology

Interesting analysis of the progress in precision oncology

Tumor patients with mutant RAS possess a worse prognosis and shorter overall survival compared with those patients without RAS mutation. Emerging strategies have been recently developed for RAS-targeting therapy. This blog post explores the ‘undruggable’ oncology target RAS, inhibitory techniques used on downstream pathways, and the preclinical models available to test up-and-coming RAS targeted agents. #CancerResearch #Oncology